Form 4: Myriad Genetics CSO Executes Tax-Related Share Withholding
Statement of Changes in Beneficial Ownership
Chief Scientific Officer Dale Muzzey disposed of 946 shares of Myriad Genetics common stock to satisfy tax obligations.
Summary
- Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reported the disposition of 946 shares of common stock.
- The transaction occurred on April 14, 2026, at a price of $4.91 per share.
- The shares were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units.
- Following this transaction, the reporting person maintains beneficial ownership of 326,310 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it is a mandatory administrative transaction related to tax compliance rather than a market-driven trade.
Positives
- The transaction was a routine administrative action related to tax obligations rather than a discretionary sale.
- The reporting person retains a significant equity stake of 326,310 shares, aligning interests with shareholders.
Negatives
- The filing reflects a reduction in the total number of shares held by the Chief Scientific Officer.
Risks
- None identified; this is a standard tax-withholding event.
Future Outlook
No forward-looking guidance or strategic outlook provided in this filing.
Industry Context
StockSavvy.ai notes that tax-related share withholding is a standard corporate governance practice for executives receiving equity-based compensation and does not typically signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction follows standard SEC reporting requirements for executive equity compensation.
- The use of 'sell-to-cover' or withholding shares for taxes is a common practice among publicly traded biotechnology firms.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a routine tax-related adjustment.
Key Dates
| Date | Description |
|---|---|
| 04/14/2026 | Date of the transaction involving the withholding of shares. |
| 04/15/2026 | Date the Form 4 was signed and filed. |
Keywords
Myriad Genetics, MYGN, Insider Trading, Form 4, Tax Withholding, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.